logo
Twitter
Discord
Email
logo
Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc.

NASDAQ•DNTH
CEO: Mr. Marino Garcia M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2018-06-21
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Contact Information
7 Times Square, 43rd Floor, New York, NY, 10036, United States
929-999-4055
dianthustx.com
Market Cap
$1.49B
P/E (TTM)
-12.3
40.6
Dividend Yield
--
52W High
$45.46
52W Low
$13.37
52W Range
87%
Rank62Top 82.4%
2.3
F-Score
Modified Piotroski Analysis
Based on 9-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2017-2025

Financial Dashboard

Q3 2025 Data

Revenue

$396.00K-81.77%
4-Quarter Trend

EPS

-$0.97+31.08%
4-Quarter Trend

FCF

-$30.56M+43.53%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Claseprubart Phase 2 Data MaGic trial showed rapid, significant efficacy improvements over placebo for claseprubart 300mg/600mg doses.
September Public Offering Raised $275.2M net cash from September 2025 public offering, bolstering liquidity position.
License Revenue Recognition Recognized $6.0M milestone revenue under Tenacia Agreements during nine months ended September 2025.
New DNTH212 Agreement Secured exclusive global rights for DNTH212 via October 2025 agreement with Leads Biolabs.

Risk Factors

Widening Net Loss Nine-month net loss reached $(97.9M) USD, significantly wider than $(56.5M) USD prior period.
Increased R&D Spending R&D expenses rose $29.1M USD to $85.7M USD for nine months, driven by clinical trials.
Continued Capital Reliance Expects to incur significant losses and rely on outside capital to fund operations for foreseeable future.
Product Approval Uncertainty Successful development and regulatory approval for claseprubart and other candidates remain highly uncertain.

Outlook

Advance Clinical Programs Anticipate initial top-line results from MoMeNtum MMN trial in second half of 2026.
DNTH212 China Initiation Plan to initiate Phase 1 study for DNTH212 in China by year-end 2025.
Fund Operations and Growth Net proceeds intended to advance preclinical/clinical activities and support working capital requirements.
CIDP Phase 3 Analysis Expect interim responder analysis for CIDP CAPTIVATE trial in second quarter of 2026.

Peer Comparison

Revenue (TTM)

Wave Life Sciences Ltd.WVE
$109.23M
+103.7%
Nektar TherapeuticsNKTR
$62.60M
-32.8%
Nuvation Bio Inc.NUVB
$26.75M
+1002.6%

Gross Margin (Latest Quarter)

Oculis Holding AGOCS
100.0%
+0.0pp
Nektar TherapeuticsNKTR
100.0%
+18.4pp
Dianthus Therapeutics, Inc.DNTH
75.0%
-25.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
PRAX$6.23B-23.7-66.9%0.1%
NUVB$3.06B-14.1-55.0%1.7%
WVE$2.79B-23.4-72.9%76.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-33.2%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 10, 2026
|
EPS:-$0.97
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 5, 2025|
    Revenue: $396.00K-81.8%
    |
    EPS: $-0.97+31.1%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $193.00K-89.6%
    |
    EPS: $-0.88+72.5%
    Meet

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 12, 2025|
    Revenue: $1.16M+33.1%
    |
    EPS: $-0.82+51.9%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 11, 2025|
    Revenue: $6.24M+120.6%
    |
    EPS: $-2.55+69.8%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $2.17M+135.1%
    |
    EPS: $-0.74-80.4%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $1.86M+92.3%
    |
    EPS: $-0.51-41.4%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 9, 2024|
    Revenue: $874.00K+83.6%
    |
    EPS: $-0.54-93.0%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 21, 2024|
    Revenue: $2.83M-56.0%
    |
    EPS: $-8.45-11.2%
    Miss